Telix Pharmaceuticals Limited (TLX) vs Viking Therapeutics, Inc. (VKTX)

Telix Pharmaceuticals Limited and Viking Therapeutics, Inc. are both Biotechnology companies. Viking Therapeutics, Inc. is the larger, with a market value of $4.3B against $3.9B — 1.1× the size. Across the 7 metrics below, Telix Pharmaceuticals Limited leads on 4 and Viking Therapeutics, Inc. on 3.

Valuation

Metric TLX VKTX Biotechnology median
P/E — n/m 7.88
P/S — n/m 11.47
P/B n/m 10.13 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield — (13.10%) (28.84%)
Free cash flow yield 0.00% (10.12%) (23.03%)

Profitability

Metric TLX VKTX Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (88.85%) (57.72%)
Return on assets 0.00% (79.24%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TLX VKTX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (120.00%) (215.84%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric TLX VKTX Biotechnology median
Debt to equity 1.18 0.00 0.00
Current ratio 2.01 4.72 4.73
Net debt to EBITDA 6.25 1.76 0.96

Dividend

Metric TLX VKTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric TLX VKTX Biotechnology median
Market cap 3.86b 4.31b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack